The topic for the September edition of the Journal Club was the recent human trial of the senolytic agents dasatinib and quercetin. For the researchers at the Mayo Clinic, this was a follow-on study from their previous human trial targeting IPF. This time the researchers ran a study to see how senolytics influenced diabetic kidney disease and if it actually removes senescent cells in humans.
The good news is that the senescent cell clearing therapy does indeed appear to work in a similar way to how it works in mice and is able to destroy harmful pro-inflammatory senescent cells which accumulate as we age. This study is admittedly small but it does suggest that these particular agents are effective in humans and not just mice and that they have potential for therapies aimed at delaying or even reversing some age-related conditions and diseases.
Hickson, L. J., Prata, L. G. L., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., … & Kellogg, T. A. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine.